DETERMINANTS OF SERUMS CAPACITY OF ACCEPT CHOLESTEROL

De La Llera-Moya博士出生在古巴，移民到这个国家 1960年。她是美国公民。她是一位有能力的科学家， 在美国接受她所有的科学训练。莫亚博士最近 转到生物化学系的学术研究职位 阿勒格尼健康科学大学，MCP霍尼曼学院 用药后花了一段时间指导一种专门的临床脂质 实验室将支持华盛顿大学医学院的血脂紊乱诊所 宾夕法尼亚医院。莫亚博士开发了一项有趣的实验 调查影响细胞胆固醇的血清因素的系统 特别强调高密度脂蛋白在这一过程中的作用。这 应用程序的中心是进一步开发这一潜在的重要 方法论。尽管目前认为高密度脂蛋白 组分在多余组织的运输中起着至关重要的作用 胆固醇到肝脏排泄，高密度脂蛋白是异质性的，而 参与这一重要功能的高密度脂蛋白的特定部分尚未被 已确认身份。此外，目前还不清楚血清因素与哪些因素相互作用 高密度脂蛋白，以促进其胆固醇的运输功能。这是不完整的 了解高密度脂蛋白的功能具有重要的临床意义， 尽管高密度脂蛋白水平与降低冠心病风险有关，但并不是所有 高密度脂蛋白水平异常低的个体同样受到威胁。此外，它还 根本不清楚什么是适当的治疗干预措施 调节高密度脂蛋白水平，降低冠心病风险。莫亚博士目前的任命 在MCP生物化学系，HSM给了她最好的可能 支持她的工作，因为她的赞助人和其他高级成员在 该部门在这一领域有成功研究的既定记录 高密度脂蛋白新陈代谢。因此，所有相关的设备、方法和 将很容易获得专业知识，以确保富有成效地完成 在此应用程序中工作。

Dr. M. E. De La Llera-Moya was born in Cuba and emigrated to this country in 1960. She is a USA citizen. She is a competent scientist and has receive all her scientific training in the States. Dr. Moya has recently moved into an academic research position in the Biochemistry Department at the Allegheny University of the Health Sciences, MCP Hohneman School of Medicine after spending some time directing a specialized clinical lipid laboratory to support a Lipid Disorders Clinic at the Medical College of Pennsylvania Hospital. Dr. Moya has developed an interesting experimental system to investigate the serum factors that affect cellular cholesterol afflux with specific emphasis on the role HDL has in this process. This application centers on further development of this potentially important methodology. Although it is currently thought that the HDL lipoprotein fraction plays a crucial role in the transport of excess tissue cholesterol to the liver for excretion, HDL are heterogeneous and the specific fraction of HDL involved in this important function has not been identified. In addition it is not clear what serum factors interact with HDL to facilitate its cholesterol-transport function. This incomplete understanding of HDL function has important clinical implications since, although high levels of HDL are linked to decreased risk of CAD, not all individuals with abnormally low HDL are equally threatened. Moreover it is not at all clear what are the appropriate therapeutic interventions to modulate HDL levels and reduce CAD risk. Dr. Moya's present appointment in the Biochemistry Department at MCP HSM gives her the best possible support for her work since her sponsor and the other senior members in the department have an established record of successful research in the area of HDL metabolism. Thus all the pertinent equipment, methodology and the expertise will be easily accessible to insure fruitful completion of the work in this application.